Karo Bio Presents Positive KB2115 Phase IIa Proof of Concept Data at Two Major Scientific Meetings
HUDDINGE, Sweden, Oct. 4, 2007- KB2115 induces a profound and clinically relevant lowering of a number of risk factors for development of cardiovascular disease and was well tolerated in the first clinical phase 2 study. Key data will now be presented at two scientific meetings. The first presentation will be made later today, October 5, at the DALM (Drugs Affecting Lipid Metabolism) meeting in New York. The second presentation will be made on October 6 at the 78th Annual Meeting of the American Thyroid Association in New York.
A separate press release including selective scientific data will be made public on Monday, October 8, 2007.
Facts about Karo Bio
Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases.
The company has expanded from being a drug discovery company by adding in-house preclinical and clinical development resources and competence for development of drugs to treat metabolic diseases. The company has a strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis and dyslipidemia. In all of these areas there are significant market opportunities and a growing need for new pharmaceuticals with new mechanisms of action.
In addition to the proprietary projects Karo Bio has two strategic collaborations with international pharmaceutical companies and one biotech collaboration for development of innovative therapies for the treatment of common diseases.
Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters: KARO.ST).
For further information, please contact: Per Olof Wallström, President & Chief Executive Officer Telephone: +46 8 608 60 20
Per Otteskog, Senior Vice President Telephone: +46 70 632 7527
Posted: October 2007